Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

Healthy Clinical Trial

Official title:

A Phase I, Randomized, Double-blind, Placebo-controlled Dose Escalation Trial to Assess the Safety Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04652297
• Other study ID #: HS-10356-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 2020
• Est. completion date: August 2021

Study information

• Verified date: November 2020
• Source: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Contact: Xiaojian Zhang, BS
• Phone: 086-0371-66913047
• Email: Zhxj0524[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess the safety and tolerability of single and multiple oral administration of HS-10356 in healthy volunteers.

Description:

This is a phase I, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to assess the safety, tolerability, and pharmacokinetics of HS-10356 oral formulation in Chinese healthy adult volunteers.

Approximately five sequential dose panels (single oral doses of 2,6,15,30,45mg HS-10356) will be evaluated in SAD. To protect the safety of volunteers, two sentinel volunteers were first enrolled in the first dose panel (2mg panel) and randomly assigned to HS-10356 or placebo in a 1:1 ratio. After the sentinel volunteers were given the dose for at least 24 hours and confirmed that they were safe, the remaining 6 volunteers were randomly assigned to HS-10356 or placebo in a ratio of 5:1. For the follow-up panels of SAD, volunteers were randomly assigned to either the experimental group or the placebo group (6 cases in HS-10356 and 2 cases in placebo) in a 3:1 ratio using block randomization method. Approximately three sequential dose panels (14 consecutive days for respectively daily oral doses of 6,15,30mg HS-10356, QD) will be evaluated in MAD. Volunteers were randomly assigned to either the experimental group or the placebo group (9 cases in the HS-10356 and 3 cases in the placebo) in a ratio of 3:1 using block randomization method. Each subject will receive only one regimen in this study. Safety data up to Day12 (±2) in SAD and up to Day25 (±2) in MAD will be reviewed prior to dose escalation. Cohorts of SAD and MAD will be added or removed depending on the assessment results of SRC.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 76
• Est. completion date: August 2021
• Est. primary completion date: August 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

Volunteers must meet all of the following inclusion criteria to be eligible for participation in this study:

1. Full understanding of the content, process and possible adverse reactions of the study, and sign the ICF voluntarily;

2. Healthy Volunteers between 18 and 55 years of age (including the critical value);

3. Male weight is not less than 50 kg, female weight is not less than 45 kg. The body mass index (BMI = weight (kg)/height (m2). The BMI should be controlled within the range of 18 to 26 (including the critical value);

4. Volunteers agree to refrain from smoking, drinking alcohol. Avoid xanthine or caffeine (including chocolate, tea, coffee, cola, etc.) and avoid strenuous exercise;

5. Agreed to use effective contraception from the date of signing of the ICF until six months after the last administration;

6. The male volunteers agreed to refrain from donating sperm from the start of the drug until six months after they stopped the study;

7. The female volunteers agreed to avoid ovum donation from the start of the drug until six months after they stopped the study;

8. Pregnancy test results of female volunteers must be negative within 3 days of administration.

Exclusion Criteria:

1. Pregnant and breastfeeding female.

2. Volunteers with a history of cardiovascular, respiratory, liver, kidney, digestive tract, mental, neurological, hematological, metabolic and other systemic diseases, who are not suitable to participate in this study as assessed by the investigator.

3. The results of vital signs, physical examination, laboratory examination and 12-lead ECG during screening were abnormal with clinical significance.

4. Major surgery was performed within 3 months prior to the screening or surgery was planned during the study.

5. Severe infections, such as cellulitis, pneumonia, sepsis, have occurred or are present in the 30 days prior to screening.

6. ALT, AST, ALP or bilirubin were higher than the upper limit of normal.

7. Creatinine clearance < 90mL/min at screening (Cockcroft-Gault method), as follows:

(140-age in years)×weight (kg)/72×serum creatinine(mg/dL)×(Female×0.85);

8.Hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCVAb), human immunodeficiency virus antibody (HIVAb) or syphilis antibody is positive.

9.Volunteers had a history of drug dependence or abuse.

10.A heavy smoker or smokers who smoked 5 or more cigarettes per day for 3 months prior to screening or tested positive for nicotine during screening.

11.A history of alcohol abuse or a single consumption of more than 14 units of alcohol (1 unit = 285 mL of beer, 25 mL of spirits, 150 mL of wine) in the nearly two weeks prior to screening or a positive breath test for alcohol at screening.

12.Participate in clinical trials of any drug or medical device within 3 months prior to screening.

13.Blood donation or blood loss = 400mL within 3 months prior to screening, or blood transfusion received; Blood donation or blood loss = 200mL within 1 month before screening.

14.Volunteers received systemic steroid, immunomodulator, or chemotherapy in the 3 months prior to screening,or likely to be treated with these drugs such as corticosteroids, immunoglobulin, and other immune or cytokine therapy during the study period.

15.Gastrointestinal ulcer, gastroesophageal reflux disease, or other severe symptoms of excess gastric acid secretion.

16.Medical or surgical treatment that permanently alters oral drug absorption and excretion, such as Gastric or intestinal surgery. Cholecystectomy, appendectomy and hernia repair are excluded.

17.Potent CYP3A4 inhibitors and potent CYP3A4 inducers was used within 28 days before administration.

18.Any medication taken within 2 weeks of administration, including prescription, over-the-counter, and herbal medicines.

19.Grapefruit juice, grapefruit and Seville orange juice were consumed in the 2 weeks prior to administration.

20.Diet or dietary treatment or significant change in dietary habits within 30 days prior to administration for whatever reason.

21.Volunteers who have difficulty swallowing solid tablets or capsule. 22.Volunteers with difficulty in blood collection, unable to tolerate multiple venous blood collection and any blood collection contraindications.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• HS-10356
Single dose of HS-10356
• Placebo
Single dose of Placebo
• HS-10356
Multiple doses of HS-10356
• Placebo
Multiple doses of Placebo

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence, severity, and association of AE, SAE, and adverse events leading to withdrawal from the trial		SAD: Day1~Day12
Primary	The incidence, severity, and association of AE, SAE, and adverse events leading to withdrawal from the trial		MAD: Day1~Day25
Primary	Laboratory assessment:Haematology		Predose, day 6 prior to discharge from hospital in SAD.
Primary	Laboratory assessment:Haematology		Predose, day4?day7?day10?day14?day19 prior to discharge from hospital in MAD
Primary	Laboratory assessment:Clinical Chemistry		Predose, day 6 prior to discharge from hospital in SAD.
Primary	Laboratory assessment:Clinical Chemistry		Predose, day4?day7?day10?day14?day19 prior to discharge from hospital in MAD
Primary	Laboratory assessment:Routine Urinalysis		Predose, day 6 prior to discharge from hospital in SAD.
Primary	Laboratory assessment:Routine Urinalysis		Predose, day4?day7?day10?day14?day19 prior to discharge from hospital in MAD
Primary	Laboratory assessment:Coagulation test		Predose, day 6 prior to discharge from hospital in SAD.
Primary	Laboratory assessment:Coagulation test		Predose, day4?day7?day10?day14?day19 prior to discharge from hospital in MAD
Primary	Vital signs:Blood pressure		Within 1 hour before administration,1hour, 2hours, 4hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 120hours after administration in SAD.
Primary	Vital signs:Blood pressure		Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14, once a day on days 15 to 19 in MAD
Primary	Vital signs:Pulse rate		Within 1 hour before administration, 1hour, 2hours, 4hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 120hours after administration in SAD.
Primary	Vital signs:Pulse rate		Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14, once a day on days 15 to 19 in MAD
Primary	Vital signs:Respiratory rate		Within 1 hour before administration, 1hour, 2hours, 4hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 120hours after administration in SAD.
Primary	Vital signs:Respiratory rate		Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14, once a day on days 15 to 19 in MAD
Primary	Vital signs:Temperature		Within 1 hour before administration,1hour, 2hours, 4hours, 12hours, 24hours, 48hours, 72hours, 96hours, and 120hours after administration in SAD.
Primary	Vital signs:Temperature		Within 1 hour before administration, 1hours, 2hours, 4hours, 12hours on days 1,2,4,6,8,10,12 and 14,once a day on days 15 to 19 in MAD
Primary	Physical examination:General		2hours, 24hours and 120hours after administration in SAD.
Primary	Physical examination:General		24hours after the first and last administration, prior to discharge from hospital in MAD
Primary	Physical examination:Lymph node		2hours, 24hours and 120hours after administration in SAD.
Primary	Physical examination:Lymph node		24hours after the first and last administration, prior to discharge from hospital in MAD
Primary	Physical examination:Chest		2hours, 24hours and 120hours after administration in SAD.
Primary	Physical examination:Chest		24hours after the first and last administration, prior to discharge from hospital in MAD
Primary	Physical examination:Abdominal		2hours, 24hours and 120hours after administration in SAD.
Primary	Physical examination:Abdominal		24hours after the first and last administration, prior to discharge from hospital in MAD
Primary	12-lead electrocardiogram (ECG) parameters ( Heart rate, PR, R-R, QRS and QTcF (average))		Within 1 hour before administration,1hours, 2hours, 3hours, 24hours 120hours after administration in SAD.
Secondary	SAD pharmacokinetic endpoint:The maximum plasma concentration (Cmax)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:Time to Cmax (Tmax)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration (AUC0-t)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC0-8)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:Terminal rate constant (?z)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:Half life (t½)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:Apparent clearance following extravascular administration (CL/F)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:Apparent volume of distribution following extravascular administration (Vd/F)		Day1-Day6
Secondary	SAD pharmacokinetic endpoint:Mean residence time (MRT)		Day1-Day6
Secondary	MAD pharmacokinetic endpoint:The maximum steady state drug concentration in plasma during dosing interval (Css,max)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:The minimum steady state drug concentration in plasma during dosing interval (Css,min)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:Average steady state drug concentration in plasma during dosing interval (Css,av)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:Time to Css, max (Tss,max)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:The area under the plasma concentration-time curve over the dosing interval at steady state (AUCss)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero to the time of the last measurable concentration at steady state(AUC0-t)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:The area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC0-8) at steady state		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:Half life (t½)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:Accumulation ratio (Rac)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:Apparent clearance at steady state following extravascular administration (CLss/F)		Day1-Day19
Secondary	MAD pharmacokinetic endpoint:Apparent volume of distribution at steady state following extravascular administration (Vd/F)		Day1-Day19